Decision & Action-Item Log — GLPI-103 Program
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The decision and action-item log — the record of key program decisions and their rationale.
Why it exists. Reviewers and auditors ask why choices were made. A decision log captures the rationale, alternatives, and owner for significant decisions, creating a defensible audit trail.
How it is produced here. It is a quality record: a plan or log that shows how the program controls quality and builds the audit trail sitting behind every other document.
Format & governing standard. Project governance (audit trail)
Decision & Action-Item Log — GLPI-103 Program
| Field | Value |
|---|---|
| Document ID | PM-DECISION |
| Version | 1.0 |
| Standard | Project governance (audit trail) |
| Confidentiality | Confidential |
Records key governance decisions and their rationale (complements PM-004 Risk Register and QA-ISSUE).
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Project Management | Initial log |
Decision Log
| ID | Date | Decision | Rationale | Owner |
|---|---|---|---|---|
| DEC-001 | 2026-06-29 | Document actual enrollment (900), not planned 900 | Realistic under-enrollment; honest reporting | RA/Biostat |
| DEC-002 | 2026-06-29 | Right-size early-phase N (SAD 40 / MAD 40 / Ph2 240) | Early-phase N driven by dose-levels×cohort, not power; cost/ethics (PM-003) | Clinical/PM |
| DEC-003 | 2026-06-29 | Ground demographics in Nemotron-Personas-Korea + T2DM prevalence | Realistic Korean T2DM population | Biostat |
| DEC-004 | 2026-06-29 | Map Korean SC values to English CDISC CT | XPORT encoding + submission standard | DM |
| DEC-005 | 2026-06-29 | No REMS for FDA; labeling-based risk management | Class precedent; risks manageable by labeling | RA-US/PV |
| DEC-006 | 2026-06-29 | Substitute subset CDISC validator for headless Pinnacle 21 | P21 registration-gated GUI; honest alternative + manual steps | DM/QA |
Action Items
| ID | Action | Owner | Due | Status |
|---|---|---|---|---|
| ACT-001 | Run official Pinnacle 21 and append report (SDRG §6) | DM | TBD | Open |
| ACT-002 | Populate M4 nonclinical study reports beyond stubs | Nonclinical | TBD | Open |
Comments (0)
No comments yet. Be the first to say something!